Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10414868 | 0.71 | NQO1 (0.50) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL12674462 | 0.64 | NQO1 (0.44) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL5925893 | 0.63 | LMNA (0.40) | KDM4EALDH1A1PLAULMNA | |
| SCHEMBL17298251 | 0.61 | — | — | |
| SCHEMBL14166403 | 0.58 | NQO1 (0.39) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL9870212 | 0.58 | NQO1 (0.39) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL11834767 | 0.58 | LMNA (0.43) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL34472783 | 0.58 | LMNA (0.58) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL11836648 | 0.58 | LMNA (0.58) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL31634339 | 0.58 | LMNA (0.43) | NQO1KDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578176-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu, Qing-Bin (CA) | 2019-12-11 | — | — | EP | disclosed |
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | LU QING BIN (CA) | 2019-11-05 | — | — | US | disclosed |
| US-9655965-B2 | Radiosensitizer compounds for use in combination with radiation | Lu qing-bin (CA) | 2017-05-23 | — | — | US | disclosed |
| US-20160235743-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu qing-bin (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235743-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu qing-bin (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20150343059-A1 | RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION | Lu qing-bin (CA) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | TOP2B, POLR2B, RB1 | NQO1 639/4885KDM4E 1734/4885ALDH1A1 893/4885 |
| US-20150343059-A1 | RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION | RB1, ERCC2, RBBP7 | NQO1 124/4885KDM4E 1183/4885ALDH1A1 172/4885 |
| US-20160235743-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | TOP2B, POLR2B, RB1 | NQO1 639/4885KDM4E 1734/4885ALDH1A1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.